.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Deloitte
Merck
McKesson
Dow
Fuji
Medtronic
Teva
Mallinckrodt
Cantor Fitzgerald

Generated: July 29, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,722,021 protect, and when does it expire?


Patent ► Subscribe protects FINACEA and is included in one NDA. There has been one Paragraph IV challenge on Finacea.

This patent has one hundred and thirty-three patent family members in nineteen countries.

Summary for Patent: ► Subscribe

Title:Foamable carriers
Abstract: The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents.
Inventor(s): Friedman; Doron (Karmei Yosef, IL), Besonov; Alex (Rehovot, IL), Tamarkin; Dov (Ness Ziona, IL), Eini; Meir (Ness Ziona, IL)
Assignee: Foamix Ltd. (Rehovot, IL)
Application Number:13/786,902
Patent Claim Types:
see list of patent claims
Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
FINACEA
azelaic acid
AEROSOL, FOAM;TOPICAL207071-001Jul 29, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel152486Oct 25, 2002

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,622,947Foamable composition combining a polar solvent and a hydrophobic carrier► Subscribe
9,636,405Foamable vehicle and pharmaceutical compositions thereof► Subscribe
8,114,385Oleaginous pharmaceutical and cosmetic foam► Subscribe
8,518,378Oleaginous pharmaceutical and cosmetic foam► Subscribe
9,101,662Compositions with modulating agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO)2008075207► Subscribe
World Intellectual Property Organization (WIPO)2008038147► Subscribe
World Intellectual Property Organization (WIPO)2008038140► Subscribe
World Intellectual Property Organization (WIPO)2007102052► Subscribe
World Intellectual Property Organization (WIPO)2007099396► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Teva
Baxter
Boehringer Ingelheim
Healthtrust
Accenture
Cipla
Daiichi Sankyo
Covington
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot